A press release from Boston Scientific reports that the firm has begun patient recruitment and enrollment in their MultiSENSE Clinical Trial. This trial is intended to evaluate physiological sensors that are in Boston Scientific’s COGNIS cardiac resynchronization therapy defibrillators with an eye toward combining them with the company’s LATITUDE Patient Management System, allowing remote monitoring and notification of heart failure.
From the press release:
Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure. The first patient was enrolled by Paul Coffeen, M.D., Austin Heart, Austin, Texas, where Jeffrey Whitehill, M.D., Medical Chair, Electrophysiology Department, is the site’s Principal Investigator.
When combined with the Company’s LATITUDE® Patient Management System, CRT-D sensors would be able to monitor a patient outside of a clinical setting and permit the LATITUDE system to deliver early notification to the physician when the patient’s heart failure worsens.
Press release: Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial…
ClinicalTrials.gov: Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices (MultiSENSE)…